Literature DB >> 20970404

Structure and lipid interactions of an anti-inflammatory and anti-atherogenic 10-residue class G(*) apolipoprotein J peptide using solution NMR.

Vinod K Mishra1, Mayakonda N Palgunachari, Jason S Hudson, Ronald Shin, Tamara D Keenum, N Rama Krishna, G M Anantharamaiah.   

Abstract

The surprising observation that a 10-residue class G(⁎) peptide from apolipoprotein J, [113-122]apoJ, possesses anti-inflammatory and anti-atherogenic properties prompted us to delineate its structural characteristics in the presence of normal and oxidized lipid. Towards this, we have determined high-resolution structure of [113-122]apoJ in solution using nuclear magnetic resonance (NMR) spectroscopy and studied its interaction with lipids, including oxidized lipids, using a number of biophysical methods. Circular dichroism and NMR studies established that in the presence of dodecylphosphocholine (DPC) micelle, this peptide adopts amphipathic α-helical structure. The observed Nuclear Overhauser effects indicate that the amphipathic helical structure of the peptide is stabilized by the N-terminal acetyl and C-terminal amide blocking groups. We used isothermal titration calorimetry to measure binding enthalpy of the peptide with DPC micelle, an oxidized lipid, 1-(palmitoyl)-2-(5-keto-6-octene-dioyl) phosphatidylcholine (KOdiA-PC), and the mixture of these two lipids (5mol% KOdiA-PC in DPC micelle). We find that the peptide binding with DPC micelle is associated with an enthalpy change (-16.75±0.16 Kcal/mol) much larger than that resulting from the binding with KodiA-PC (-3.67±0.13 Kcal/mol). Incorporation of a small amount of KOdiA-PC (5mol%) in DPC micelle also results in the lowering of peptide binding enthalpy (-13.43±0.18 Kcal/mol). These results are consistent with overall negative charge and altered conformational properties of oxidized sn-2 chain of KOdiA-PC. Our results have unambiguously established the amphipathic α-helical structure of [113-122]apoJ peptide in the presence of DPC micelle as well as its ability to bind oxidized lipid. These in vitro results help explain the previously observed anti-inflammatory and anti-atherosclerotic properties of this peptide.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20970404      PMCID: PMC2997858          DOI: 10.1016/j.bbamem.2010.10.011

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  40 in total

Review 1.  Oxidized phospholipids as endogenous pattern recognition ligands in innate immunity.

Authors:  Stanley L Hazen
Journal:  J Biol Chem       Date:  2008-02-19       Impact factor: 5.157

2.  Proton nuclear magnetic resonance assignments.

Authors:  V J Basus
Journal:  Methods Enzymol       Date:  1989       Impact factor: 1.600

3.  5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice.

Authors:  Marcelo J A Amar; Wilissa D'Souza; Scott Turner; Stephen Demosky; Denis Sviridov; John Stonik; Jayraz Luchoomun; Jason Voogt; Marc Hellerstein; Dmitri Sviridov; Alan T Remaley
Journal:  J Pharmacol Exp Ther       Date:  2010-05-19       Impact factor: 4.030

4.  Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit.

Authors:  J J Badimon; L Badimon; V Fuster
Journal:  J Clin Invest       Date:  1990-04       Impact factor: 14.808

5.  A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice.

Authors:  John K Bielicki; Haiyan Zhang; Yuan Cortez; Ying Zheng; Vasanthy Narayanaswami; Arti Patel; Jan Johansson; Salman Azhar
Journal:  J Lipid Res       Date:  2010-01-14       Impact factor: 5.922

Review 6.  Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels.

Authors:  Derek J Hausenloy; Derek M Yellon
Journal:  Curr Opin Cardiol       Date:  2009-09       Impact factor: 2.161

7.  A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all L-amino acids.

Authors:  Mohamad Navab; Piotr Ruchala; Alan J Waring; Robert I Lehrer; Susan Hama; Greg Hough; Mayakonda N Palgunachari; G M Anantharamaiah; Alan M Fogelman
Journal:  J Lipid Res       Date:  2009-02-18       Impact factor: 5.922

Review 8.  Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.

Authors:  D J Hausenloy; D M Yellon
Journal:  Heart       Date:  2008-06       Impact factor: 5.994

9.  Effect of leucine to phenylalanine substitution on the nonpolar face of a class A amphipathic helical peptide on its interaction with lipid: high resolution solution NMR studies of 4F-dimyristoylphosphatidylcholine discoidal complex.

Authors:  Vinod K Mishra; Mayakonda N Palgunachari; Rama Krishna; John Glushka; Jere P Segrest; G M Anantharamaiah
Journal:  J Biol Chem       Date:  2008-10-09       Impact factor: 5.157

10.  Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients.

Authors:  Leanne T Bloedon; Richard Dunbar; Danielle Duffy; Paula Pinell-Salles; Robert Norris; Bruce J DeGroot; Rajesh Movva; Mohamad Navab; Alan M Fogelman; Daniel J Rader
Journal:  J Lipid Res       Date:  2008-03-06       Impact factor: 5.922

View more
  5 in total

1.  Sidedness of interfacial arginine residues and anti-atherogenicity of apolipoprotein A-I mimetic peptides.

Authors:  Gaurav Nayyar; Vinod K Mishra; Shaila P Handattu; Mayakonda N Palgunachari; Ronald Shin; David T McPherson; Champion C S Deivanayagam; David W Garber; Jere P Segrest; G M Anantharamaiah
Journal:  J Lipid Res       Date:  2012-02-29       Impact factor: 5.922

Review 2.  Lipid peroxidation generates biologically active phospholipids including oxidatively N-modified phospholipids.

Authors:  Sean S Davies; Lilu Guo
Journal:  Chem Phys Lipids       Date:  2014-04-02       Impact factor: 3.329

3.  High-Resolution Structural Studies Elucidate Antiatherogenic and Anti-Inflammatory Properties of Peptides Designed to Mimic Amphipathic α-Helical Domains of Apolipoprotein A-I.

Authors:  Vinod K Mishra; Gattadahalli M Anantharamaiah
Journal:  Nat Prod Commun       Date:  2019-05-28       Impact factor: 1.496

4.  Effects of an Aβ-antibody fragment on Aβ aggregation and astrocytic uptake are modulated by apolipoprotein E and J mimetic peptides.

Authors:  Laia Montoliu-Gaya; Sandra D Mulder; Robert Veerhuis; Sandra Villegas
Journal:  PLoS One       Date:  2017-11-20       Impact factor: 3.240

5.  Subcutaneous Administration of Apolipoprotein J-Derived Mimetic Peptide d-[113-122]apoJ Improves LDL and HDL Function and Prevents Atherosclerosis in LDLR-KO Mice.

Authors:  Andrea Rivas-Urbina; Anna Rull; Joile Aldana-Ramos; David Santos; Nuria Puig; Nuria Farre-Cabrerizo; Sonia Benitez; Antonio Perez; David de Gonzalo-Calvo; Joan Carles Escola-Gil; Josep Julve; Jordi Ordoñez-Llanos; Jose Luis Sanchez-Quesada
Journal:  Biomolecules       Date:  2020-05-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.